Sathgen Therapeutics completes dosing of the first two cohorts of healthy volunteers with MSP008-22, a novel anti-viral drug
(Adnkronos) – MSP008-22 is a new drug candidate that shows excellent efficacy against a range of viruses during preclinical development MUMBAI, India, Aug. 9, 2023 /PRNewswire/ — Sathgen Therapeutics, a division of
